Enhancement of the myotic response of rabbits with pilocarpine-loaded polybutylcyanoacrylate nanoparticles

Harmia, T.; Kreuter, Jörg; Speiser, P; Boye, T.; Gurny, Robert; Kubi, A.

doi:10.1016/0378-5173(86)90053-0

Cited by 55 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PNPs can be developed from synthetic and natural biocompatible polymers. The first PNPs developed for ocular applications were made from poly‐(alkyl cyanoacrylates) . To date, various other polymers, such as polycaprolactone, chitosan, hyaluronic acid (HA), Eudragit (RS100 and RL100), Carbopol, gelatin, poly‐(butylcyanoacrylate), poly lactic acid (PLA), and poly‐(lactic‐co‐glycolic acid) (PLGA) have been used for the fabrication of PNPs for ocular applications .…”

Section: Nanostructured Drug Delivery Systemsmentioning

confidence: 99%

Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases

Bisht

Mandal

Jaiswal

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Effective drug delivery to the retina still remains a challenge due to ocular elimination mechanisms and complex barriers that selectively limit the entry of drugs into the eye. To overcome these barriers, frequent intravitreal injections are currently used to achieve high drug concentrations in vitreous and retina. However, these repetitive injections may result in several side effects. Recent advancements in the field of nanoparticle-based drug delivery could overcome some of these unmet needs and various preclinical studies conducted to date have demonstrated promising results of nanotherapies in the treatment of retinal diseases. Compared to the majority of commercially available ocular implants, the biodegradable nature of most nanoparticles (NPs) avoids the need for surgical implantation and removal after the release of the payload. In addition, the sustained drug release from NPs over an extended period of time reduces the need for frequent intravitreal injections and the risk of associated side effects. The nanometer size and highly modifiable surface properties make NPs excellent candidates for targeted ocular drug delivery. Studies have shown that nanocarriers enhance the intravitreal half-life and thus bioavailability of a number of drugs including proteins and peptides. In addition, they have shown promising results in delivering genetic material to the retinal tissues by protecting it from possible intravitreal degradation. This review covers the various challenges associated with drug delivery to the posterior segment of the eye, particularly the retina, and highlights the application of nanocarriers to overcome these challenges in context with recent advances in preclinical studies. WIREs Nanomed Nanobiotechnol 2018, 10:e1473. doi: 10.1002/wnan.1473 This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Implantable Materials and Surgical Technologies > Nanomaterials and Implants.

show abstract

Section: Nanostructured Drug Delivery Systemsmentioning

confidence: 99%

Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases

Bisht

Mandal

Jaiswal

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Formulations in the form of hydrogels, micro-and nanoparticles, liposomes and collagen shields have been investigated [1]. Among these, nanoparticles have often been shown to provide efficient ocular drug delivery systems [2][3][4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Enhanced Ocular Anti-Inflammatory Activity of Ibuprofen Carried by an Eudragit RS100<sup>®</sup> Nanoparticle Suspension

et al. 2002

View full text Add to dashboard Cite

Purpose: To investigate the ocular pharmacodynamic profile of a polymer nanoparticle system loaded with sodium ibuprofen (IBU-RS) in comparison to an aqueous solution of ibuprofen lysinate (IBL) in the rabbit eye both being applied topically. Methods: Ocular inflammation was elicited by topical application of sodium arachidonate. Inflammation was quantified according to a modified Draize test. The protein level and the number of polymorphonuclear leukocytes in the aqueous humor were assessed after 2 h from arachidonate instillation. The ibuprofen concentration in the aqueous humor was evaluated by HPLC assay. The physico-chemical properties of nanoparticles were also evaluated. Results: The IBU-RS nanosuspension formulation significantly reduced the primary signs of ocular inflammation as well as significantly reducing the protein level and the number of polymorphonuclear leukocytes in the aqueous humor compared with the IBL formulation. Furthermore, the aqueous humor drug concentration from the group treated with IBU-RS was significantly higher compared to the IBL-treated group. The IBU-RS nanosuspensions showed very interesting size and surface charge values, adequate for ophthalmic administration. Conclusions: The pharmacological profile of the topical IBU-RS nanosuspension formulation described in this study indicates that the dispersion of the drug within RS polymer nanoparticles increased its ocular bioavailability and ultimately its pharmacological activity.

show abstract

“…Synthetic and natural biocompatible polymers can be used to develop PNPs. The polymers used to generate PNPs for ocular applications have been made from poly(alkyl cyanoacrylates) [83,84], polycaprolactone, chitosan (CS), hyaluronic acid (HA), Eudragit (RS100 and RL100), Carbopol, gelatin, poly(butyl cyanoacrylate), polylactic acid (PLA), and poly(lactic-co-glycolic acid) (PLGA) [57,85].…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Breaking down the Barrier: Topical Liposomes as Nanocarriers for Drug Delivery into the Posterior Segment of the Eyeball

Santos¹,

Altamirano-Vallejo²,

Navarro-Partida³

et al. 2020

Role of Novel Drug Delivery Vehicles in Nanobiomedicine

View full text Add to dashboard Cite

Topical instillation is the most widely preferred noninvasive route of drug administration to treat diseases affecting the anterior segment of the eye. Nonetheless, the ocular bioavailability for deeper ocular tissues is very low. Different routes of administration, such as intravitreal injections, periocular injections, and systemic administration, have been used to deliver drugs into the posterior segment ocular tissues. However, the presence of blood-retinal barriers (BRBs) makes systemic administration an impractical approach, whereas the drug delivery with the periocular administration route is compromised by ocular static and dynamic barriers. On the other hand, intravitreal injection, the most common and widely recommended route for drug administration to treat posterior ocular diseases, is related to several side effects such as endophthalmitis, hemorrhage, retinal detachment, and poor patient tolerance. Diverse strategies to overcome ocular barriers have been explored for topical drop formulations in order to deliver drugs into the posterior segment ocular tissues. In this chapter, we will review the promising topical nanocarriers for drug delivery into the posterior segment of the eye, emphasizing the use of liposomes for topical ophthalmic formulations targeting the vitreous cavity and the retina.

show abstract

Enhancement of the myotic response of rabbits with pilocarpine-loaded polybutylcyanoacrylate nanoparticles

Cited by 55 publications

References 11 publications

Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases

Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases

Enhanced Ocular Anti-Inflammatory Activity of Ibuprofen Carried by an Eudragit RS100<sup>®</sup> Nanoparticle Suspension

Breaking down the Barrier: Topical Liposomes as Nanocarriers for Drug Delivery into the Posterior Segment of the Eyeball

Contact Info

Product

Resources

About